- |||||||||| Opdivo (nivolumab) / BMS
Trial completion, Trial completion date, Trial primary completion date: Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Aug 9, 2024 P1, N=28, Completed, N=79 --> 9 | Trial completion date: Oct 2023 --> Jan 2024 | Active, not recruiting --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> May 2024 | Trial primary completion date: Apr 2025 --> May 2024
- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment closed, Metastases: Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Aug 9, 2024 P2, N=41, Active, not recruiting, More randomised clinical trials are needed to strengthen the body of evidence and provide insight into the benefits and harms of TACE or TAE in comparison with systemic chemotherapy in people with liver metastases from colorectal cancer. Not yet recruiting --> Active, not recruiting
- |||||||||| uproleselan sodium (APL-106) / GlycoMimetics
Enrollment closed, Combination therapy: NCI-2021-10020: Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane (clinicaltrials.gov) - Aug 9, 2024 P1, N=18, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jul 2024 Recruiting --> Active, not recruiting
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Observational data, Retrospective data, Journal: Impact of Coronavirus Disease 2019 on the Diagnosis and Treatment of Pancreatic Cancer: An Observational Cohort Study. (Pubmed Central) - Aug 8, 2024 This study revealed changes in the characteristics and treatment of patients diagnosed with pancreatic cancer during the COVID-19 pandemic. Although further large-scale research is necessary, the findings of this study can function as foundational data for formulating policies for the management of patients with pancreatic cancer during future pandemics of other infectious diseases.
- |||||||||| methotrexate / Generic mfg.
Journal: A Case Report on Iatrogenic Methotrexate Toxicity. (Pubmed Central) - Aug 8, 2024 At this time, the patient had mucocutaneous lesions and was complaining of oral and throat pain, and a repeat CBC demonstrated pancytopenia. The patient was admitted to the hospital for further management and treatment of methotrexate toxicity.
- |||||||||| gemcitabine / Generic mfg.
Clinical, Retrospective data, Review, Journal, Combination therapy, Monotherapy, Metastases: Efficacy of first-line combination therapies versus gemcitabine monotherapy for advanced pancreatic cancer: a systematic review and network meta-analysis. (Pubmed Central) - Aug 8, 2024 The analysis revealed that gemcitabine+nab-paclitaxel (GA), GA with platinum and fluorouracil (GA+Plat+FU), gemcitabine with fluorouracil (G+FU), G+Plt+FU, and FOLFIRINOX were associated with superior OS and PFS compared to gemcitabine monotherapy...These findings support the use of gemcitabine-based or fluorouracil-based triplet or quadruplet regimens for better survival outcomes in patients with advanced pancreatic cancer. Further research is warranted to explore the potential benefits of adding chemotherapy agents, such as fluorouracil, to the GA doublet regimen.
- |||||||||| Enrollment closed, Phase classification, Enrollment change: FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer (clinicaltrials.gov) - Aug 7, 2024
P2, N=11, Active, not recruiting, https://www.chictr.org.cn, identifier ChiCTR2000040940. Recruiting --> Active, not recruiting | Phase classification: P2a --> P2 | N=20 --> 11
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Observational data, Journal, Real-world evidence, Real-world: A multicenter, prospective, non-interventional real-world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer. (Pubmed Central) - Aug 6, 2024 In a real-world setting, mecapegfilgrastim has proven effective in preventing severe neutropenia in gastrointestinal patients following chemotherapy. This includes commonly used moderate or high-risk FN regimens or regimens containing S1/capecitabine, all of which have demonstrated favorable efficacy and safety profiles.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Goodbye to pruritus! Dupilumab as a hero in the oncological battle (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4742; In this case, the patient presented with chronic pruritus associated with advanced colon cancer and the chemotherapy received over several years. Despite multiple therapeutic interventions, including corticosteroids, antidepressants, and phototherapy, the pruritus persisted, negatively affecting his quality of life and emotional well-being.
- |||||||||| Enrollment change, Trial termination: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - Aug 5, 2024
P1/2, N=4, Terminated, Trial completion date: Jul 2029 --> Oct 2029 | Initiation date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jul 2029 --> Oct 2029 N=65 --> 4 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: A rare case report of mucinous adenocarcinoma exacerbated by long-standing solitary rectal ulcer syndrome. (Pubmed Central) - Aug 2, 2024 Furthermore, this case adds to existing literature by presenting a rare instance of SRUS progressing rapidly to mucinous adenocarcinoma, highlighting the significance of regular monitoring and timely intervention in such cases. Further research is warranted to elucidate underlying mechanisms and risk factors, guiding future clinical practice and treatment strategies.
- |||||||||| etrumadenant (AB928) / Arcus Biosci, Gilead, quemliclustat (AB680) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date, Metastases: ARC-9: An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Aug 1, 2024 P1/2, N=227, Active, not recruiting, Further research is warranted to elucidate underlying mechanisms and risk factors, guiding future clinical practice and treatment strategies. Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Oct 2024
- |||||||||| 5-fluorouracil / Generic mfg.
A RARE CASE OF UNILATERAL PHRENIC NERVE PALSY IN ASSOCIATION WITH PLATINUM-BASED CHEMOTHERAPY (Convention Center Exhibit Hall: Poster Area 5) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5643; INTRODUCTION: Chemotherapy-induced neuropathy is a well-reported complication of many chemotherapy agents (particularly with platinum-based agents, taxanes, vinca alkaloids, thalidomide, and bortezomib) which may lead to significant morbidity and perhaps permanent disability in nearly half of cancer survivors...She received 4 cycles of chemotherapy with FOLFOX (5-fluorouracil, oxaliplatin, and leucovorin)... Platinum-based chemotherapy could be a rare possible etiology of unilateral phrenic nerve palsy leading to diaphragmatic impairment that may lead to respiratory morbidity among chemotherapy patients following the initiation of platinum-based regimes.
- |||||||||| Mycamine (micafungin) / Astellas
DUODENO-PLEURAL FISTULA: A RARE COMPLICATION OF COLON CANCER (Convention Center Exhibit Hall: Rapid Fire Area 1C) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5435; A prolonged course of Ceftriaxone, Metronidazole and Micafungin was administered... Duodeno-pleural fistula represent an exceedingly rare and difficult to treat complication of colon cancer requiring multi-disciplinary support and careful individualized care.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
PULMONARY OSSIFICATION: WHEN LUNGS GROW BONES, IT BECOMES HARD TO BREATH (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5374; Pulmonary ossification presents as a rare phenomenon with few antemortem cases and unclear etiology. While we hypothesize that medication-induced pneumonitis in the setting of COVID-19 may have led to pulmonary ossification, its clinical significance and management remain unclear, warranting further study.
- |||||||||| Avastin (bevacizumab) / Roche
ENDOBRONCHIAL VALVE AS A PALLIATIVE TREATMENT IN LIFE-THREATENING HEMOPTYSIS (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_2962; EBV placement may be considered a novel, efficacious alternative therapy for achieving hemostasis for palliative reasons. EBVs could also be considered as a treatment option for hemoptysis in non-palliative cases moving forward.
- |||||||||| TO GIVE STEROIDS OR TO NOT GIVE...IN A KAPOSI'S SARCOMA PATIENT (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_2733;
In our case, steroids were continued due to SIADH which was diagnosed at the recent hospital visit. In future cases, there is a need to set guidelines on steroid use, especially in patients with human immunodeficiency virus.
- |||||||||| Review, Journal: New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy. (Pubmed Central) - Jul 31, 2024
Recent advances in treatment protocols, such as FOLFIRINOX and gemcitabine-nab-paclitaxel, now integral to NAT strategies, have shown promising results in increasing the proportion of patients eligible for surgery by effectively reducing tumor size and addressing micrometastatic disease...Despite these advancements, the role of NAT continues to evolve, necessitating ongoing research to optimize treatment regimens, minimize adverse effects, and identify patient populations that would benefit most from these approaches. Through a detailed analysis of current literature and recent clinical trials, this review highlights the transformative potential of NAT in managing PDAC, especially in patients with borderline resectable or locally advanced stages, promising a shift towards more personalized and effective management strategies for PDAC.
- |||||||||| 5-fluorouracil / Generic mfg.
Clinical, P2/3 data, Journal, Metastases: Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. (Pubmed Central) - Jul 31, 2024 P2 Through a detailed analysis of current literature and recent clinical trials, this review highlights the transformative potential of NAT in managing PDAC, especially in patients with borderline resectable or locally advanced stages, promising a shift towards more personalized and effective management strategies for PDAC. Building on data from modern day rectal cancer trials and patient input from national advocacy groups, we have designed The Janus Rectal Cancer Trial studying chemotherapy intensification via a consolidation chemotherapy approach with the intent to enhance cCR and DFS rates, increase organ preservation rates, and improve quality of life for patients with rectal cancer.
- |||||||||| Cyramza (ramucirumab) / Eli Lilly
Journal, Metastases: Ramucirumab in second?line advanced colorectal cancer therapy: A study on therapeutic outcomes and hepatic sinusoidal platelet aggregation. (Pubmed Central) - Jul 31, 2024 Immunohistochemical analysis of CD42b showed that the platelet aggregation score (CD42b score), which ranges from 0 (absence of deposition) to 3 (presence of linear deposition), tended to decrease with the increasing duration of treatment with both RAM and BEV. Although there was no significant difference in the mean duration of anti-VEGF antibody treatment between the BEV-LM and RAM-LM groups, the median CD42b score was higher in the RAM-LM group (median CD42b score, 3; range, 0-3) compared with that in the BEV-LM group (median CD42b score, 1; range, 0-3; P=0.01), suggesting that RAM induces a different degree of platelet aggregation in liver sinusoids compared to BEV.
- |||||||||| Opdivo (nivolumab) / BMS
Journal, Mismatch repair, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: Use of Chemoimmunotherapy for Locally Advanced Deficient Mismatch Repair (dMMR) Gastric Adenocarcinoma With Curative Intent: A Case Report. (Pubmed Central) - Jul 31, 2024 Although there was no significant difference in the mean duration of anti-VEGF antibody treatment between the BEV-LM and RAM-LM groups, the median CD42b score was higher in the RAM-LM group (median CD42b score, 3; range, 0-3) compared with that in the BEV-LM group (median CD42b score, 1; range, 0-3; P=0.01), suggesting that RAM induces a different degree of platelet aggregation in liver sinusoids compared to BEV. Several phase II and III trials suggest a promising future role of immunotherapy with or without chemotherapy in the neoadjuvant/adjuvant setting, especially in MSI-H localized gastric adenocarcinomas.
- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial primary completion date: LyRICX: Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer (clinicaltrials.gov) - Jul 31, 2024 P2, N=320, Recruiting, Several phase II and III trials suggest a promising future role of immunotherapy with or without chemotherapy in the neoadjuvant/adjuvant setting, especially in MSI-H localized gastric adenocarcinomas. Trial completion date: Aug 2024 --> Jul 2026 | Trial primary completion date: Aug 2024 --> Jul 2025
|